{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-skin/prescribing-information/oral-fluconazole/","result":{"pageContext":{"chapter":{"id":"a6376d8b-e282-52b4-a990-ceb7d73afaf3","slug":"oral-fluconazole","fullItemName":"Oral fluconazole","depth":2,"htmlHeader":"<!-- begin field 5d52ddba-6bb7-4db6-8155-e944f71b4b0d --><h2>Oral fluconazole</h2><!-- end field 5d52ddba-6bb7-4db6-8155-e944f71b4b0d -->","summary":"","htmlStringContent":"<!-- begin item 962fba32-1713-4a15-9b04-9e5aac1f713f --><!-- end item 962fba32-1713-4a15-9b04-9e5aac1f713f -->","topic":{"id":"0d4d1ca9-1f95-59a6-9163-91faf2fce35e","topicId":"44d93cc7-56e9-4f35-92ee-6fe5c97d5646","topicName":"Candida - skin","slug":"candida-skin","lastRevised":"Last revised in May 2017","chapters":[{"id":"fdd77154-68fd-5e12-ab34-4980d82ec2e8","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"20e27b79-2755-56d0-811f-79d59b1ad973","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"dc171785-2e5e-50c2-9f57-0cd56c75a2d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"9ce37f9c-5801-5953-acaa-da119b97818f","slug":"changes","fullItemName":"Changes"},{"id":"a9f51671-bb82-536e-9b5f-c98cb41291e6","slug":"update","fullItemName":"Update"}]},{"id":"6f439137-5e54-571e-b7aa-8cce9c5c58f6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7433f221-a6d1-5f98-a53d-32009abd6d65","slug":"goals","fullItemName":"Goals"},{"id":"c1df0f9d-1fa3-5aa3-96a3-7636250c141a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1edcd62f-0185-5317-a25a-afb5e18d3d5e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e514a54c-ae49-5bb6-9c8e-0de16f244409","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"00336847-83a8-540e-954e-23801c8eb472","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"99dacab6-3fed-5a48-ad05-74876122fa41","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7884dd9b-ba26-56fe-8b96-29022de73f28","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3aa00866-7e3b-5a84-9b01-091a915acd1e","slug":"definition","fullItemName":"Definition"},{"id":"82ae2b5c-db02-50a0-9572-a12b245c9f9f","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"16b02723-03c7-5877-8f98-955d9ba0adda","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"3e942288-d611-5acc-a0a5-79c5a9bbf5c3","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"815a9379-3ee5-585a-997e-8daf2e138d95","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"556293f9-6cf5-5f40-bdd2-06dfff1c5b82","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d48752d8-0979-5908-b55c-40d0bf50e947","fullItemName":"Management","slug":"management","subChapters":[{"id":"187d27a6-4a3a-59f4-99c1-33a221ca0d2b","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ab1b23e6-6d8b-5003-bdea-20df2a09e2b1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"216d1aaa-ae60-548d-b753-0c53f672a4ad","slug":"topical-antifungals","fullItemName":"Topical antifungals"},{"id":"a6376d8b-e282-52b4-a990-ceb7d73afaf3","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"}]},{"id":"1b822a63-5645-5cdc-9a82-7e61da577351","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6bcfeaf8-f78c-5867-99f3-adb4fde508db","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"e9a0750e-9090-547a-aac2-eea9118c16c8","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7624a8b0-8f03-5842-b47f-0374a546f628","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e3980da9-5b2b-5ebb-a7ed-7edcff958155","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3941da5-da7c-5313-b272-7df5b0bd2985","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0839e574-758e-59d0-8520-6335161c5e49","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3603b783-48c3-58d3-a191-1fb1ff30eca8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ab1b23e6-6d8b-5003-bdea-20df2a09e2b1","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"033fae4a-2ce0-5215-ae59-d3ffb4ec5570","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field b9a0e818-0081-415e-b089-a748013d2c36 --><h3>What are the contraindication and cautions for oral fluconazole?</h3><!-- end field b9a0e818-0081-415e-b089-a748013d2c36 -->","summary":"","htmlStringContent":"<!-- begin item 2720ba76-89b4-4773-914e-a748013d2b6e --><!-- begin field 9910e52a-234b-4409-8b78-a748013d2c36 --><ul><li><strong>Do not prescribe:</strong><ul><li><strong>Oral fluconazole to:</strong><ul><li>People with acute porphyria.</li><li>Pregnant women.</li><li>People taking <a class=\"topic-reference internal-reference\" href=\"/topics/candida-skin/prescribing-information/oral-fluconazole/#drug-interactions\">certain drugs</a>.</li></ul></li><li><strong>High or repeated doses of oral fluconazole to:</strong><ul><li>Breastfeeding women.</li></ul></li></ul></li><li><strong>Prescribe oral fluconazole with caution to people:</strong><ul><li>At risk of QT interval prolongation — this includes people with cardiomyopathy, sinus bradycardia, arrhythmias, hypokalaemia, hypomagnesaemia, hypocalcaemia, and those taking other drugs known to cause QT interval prolongation (such as tricyclic antidepressants, antipsychotics, and antiarrhythmics).</li><li>With hepatic impairment or taking concurrent hepatotoxic drugs, due to the risk of hepatic necrosis — discontinue treatment if signs or symptoms of hepatic disease develop (such as severe abdominal pain, jaundice, or weakness).  </li><li>With renal impairment (estimated glomerular filtration rate [eGFR] less than 50 mL/min/1.73m<sup>2</sup>) — use the usual initial dose then halve any subsequent doses.</li><li>Who are taking <a class=\"topic-reference internal-reference\" href=\"/topics/candida-skin/prescribing-information/oral-fluconazole/#drug-interactions\">certain drugs</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">ABPI Medicines Compendium, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">BNF 72, 2016</a>]</p><!-- end field 9910e52a-234b-4409-8b78-a748013d2c36 --><!-- end item 2720ba76-89b4-4773-914e-a748013d2b6e -->","subChapters":[]},{"id":"4f77be0c-c7a0-545b-ac1e-bf0871278a2e","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 1be37554-d73f-417f-87cd-a748013d4bd0 --><h3>What are the adverse effects of oral fluconazole?</h3><!-- end field 1be37554-d73f-417f-87cd-a748013d4bd0 -->","summary":"","htmlStringContent":"<!-- begin item 8938656b-9d91-4ce8-a0ce-a748013d4bbc --><!-- begin field f522130b-78a5-4823-83e1-a748013d4bd0 --><ul><li><strong>Adverse effects </strong><strong>of oral fluconazole include the following. </strong><ul><li><strong>Common or very common:</strong><ul><li>Abdominal discomfort, diarrhoea, nausea, and flatulence.</li><li>Headache.</li><li>Rash — discontinue treatment if the infection becomes invasive or systemic.</li></ul></li><li><strong>Uncommon:</strong><ul><li>Alopecia.</li><li>Adrenal insufficiency.</li><li>Dizziness.</li><li>Vomiting, dyspepsia, and taste disturbance.</li><li>Hepatic disorders.</li><li>Hyperlipidaemia.</li><li>Seizures.</li><li>Pruritus, anaphylaxis, angioedema (in children), hypersensitivity reactions (in adults), Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li></ul></li><li><strong>Frequency unknown:</strong><ul><li>Hypokalaemia.</li><li>Leucopenia and thrombocytopenia.</li></ul></li></ul></li><li>Severe cutaneous reactions are more likely in people with AIDS.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">ABPI Medicines Compendium, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">BNF 72, 2016</a>]</p><!-- end field f522130b-78a5-4823-83e1-a748013d4bd0 --><!-- end item 8938656b-9d91-4ce8-a0ce-a748013d4bbc -->","subChapters":[]},{"id":"b4b655aa-f5f6-564d-9ef3-95712d6073a3","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field fccf4a1d-036e-4a2d-b36c-a748013d6390 --><h3>What drug interactions are associated with oral fluconazole?</h3><!-- end field fccf4a1d-036e-4a2d-b36c-a748013d6390 -->","summary":"","htmlStringContent":"<!-- begin item fe6268f1-14e4-453b-8f7f-a748013d6380 --><!-- begin field e00241b3-a0bc-4655-ba14-a748013d6390 --><ul><li><strong>Fluconazole inhibits the metabolism of drugs metabolized by the cytochrome P450 enzymes CYP2C9 (potently), CYP3A4 (moderately), and CYP2C19</strong><strong>. This may result in a higher and/or prolonged action of these drugs, including adverse effects. </strong>The enzyme-inhibiting effect of fluconazole persists 4–5 days after discontinuation of fluconazole treatment due to the long half-life of fluconazole. <ul><li><strong>The following drugs are contraindicated (or should be avoided) during treatment with fluconazole:</strong><ul><li>Ergotamine — there is an increased risk of ergotism.</li><li>Erythromycin — concurrent use with fluconazole has the potential to increase the risk of cardiotoxicity (prolonged QT interval and Torsades de Pointes) and consequently sudden heart death.</li><li>Pimozide — concurrent use with fluconazole may lead to QT prolongation and rare occurrences of Torsade de Pointes.</li><li>Quetiapine.</li><li>Reboxetine.</li></ul></li><li><strong>Concurrent treatment with f</strong><strong>luconazole and the following drugs </strong><strong>should be done with caution </strong>(concurrent use should be monitored; dose adjustments may be indicated):<ul><li>Aminophylline and theophylline.</li><li>Avanafil.</li><li>Ciclosporin.</li><li>Coumarins, such as warfarin. </li><li>Diazepam (risk of prolonged sedation).</li><li>Fentanyl.</li><li>Midazolam (risk of prolonged sedation).</li><li>Phenytoin.</li><li>Rifabutin (increased risk of uveitis).</li><li>Statins — the risk of myopathy and rhabdomyolysis increases when fluconazole is given with statins metabolized through CYP3A4 (atorvastatin and simvastatin) or through CYP2C9 (fluvastatin). If concurrent treatment is necessary, monitor for symptoms of myopathy and rhabdomyolysis, and monitor creatine kinase. Discontinue the statin if a marked increase in creatine kinase is observed or if myopathy/rhabdomyolysis is diagnosed or suspected.</li><li>Sulfonylureas (such as gliclazide and glipizide) — if concurrent use is indicated, advise the person to seek medical advice if they have symptoms of hypoglycaemia (for example nervousness, sweating, and/or trembling).</li><li>Tacrolimus and sirolimus.</li><li>Tretinoin — fluconazole possibly increases the risk of tretinoin toxicity.</li><li>Zidovudine — fluconazole increases the risk of zidovudine toxicity. </li></ul></li></ul></li><li><strong>Other possible drug interactions of fluconazole include:</strong><ul><li>Clopidogrel — fluconazole possibly reduces the antiplatelet effect of clopidogrel.</li><li>Hydrochlorothiazide — the plasma levels of fluconazole may be increased by 40%; however, no adjustment in dosage of fluconazole is required. </li><li>Rifampicin — metabolism of fluconazole may be accelerated by rifampicin, leading to reduced plasma concentrations.</li></ul></li><li><strong>For a complete </strong><strong>list of possible drug interactions of fluconazole</strong><strong>, </strong>see the <a href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\" data-hyperlink-id=\"f3b2122f-29d5-47d2-a803-a98f0175002a\">electronic Medicines Compendium</a> (eMC) or the <a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"29896935-0e7f-4dfc-a29f-a98f01750050\">British National Formulary</a> (BNF).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">ABPI Medicines Compendium, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-skin/references/\">BNF 72, 2016</a>]</p><!-- end field e00241b3-a0bc-4655-ba14-a748013d6390 --><!-- end item fe6268f1-14e4-453b-8f7f-a748013d6380 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}